Drug-induced psoriasis: an evidence-based overview and the introduction of psoriatic drug eruption probability score.
Psoriasis is a common skin disorder that needs a long-term management, not only because, of its prevalence but also because of the profound impact it can have on patients quality of life. Drugs may result in exacerbation of a preexisting psoriasis, in induction of psoriatic lesions on clinically uninvolved skin in patients with psoriasis, or in precipitation of the disease in persons without family history of psoriasis or in predisposed individuals. The knowledge of the drugs that may induce, trigger, or exacerbate the disease is of primary importance in clinical practice. By reviewing the literature, there are many reports on drug-induced psoriasis, but the data are not univocal. We propose, when possible, the use of a probability score from the authors to obtain a better classification and further understanding of drug-induced psoriasis.
Dika
Emi
E
Department of Dermatology, University of Bologna, Bologna, Italy. emi.dika@tin.it
Varotti
C
C
Bardazzi
F
F
Maibach
H I
HI
D000319:Adrenergic beta-Antagonists / Q000009:adverse effects; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000009:adverse effects; D000962:Antimalarials / Q000009:adverse effects; D002800:Cholinesterase Inhibitors / Q000009:adverse effects; D003875:Drug Eruptions / Q000145:classification* / Q000175:diagnosis; D006801:Humans; D007372:Interferons / Q000009:adverse effects; D008094:Lithium / Q000009:adverse effects; D009281:Naphthalenes / Q000009:adverse effects; D011336:Probability; D011565:Psoriasis / Q000139:chemically induced / Q000145:classification* / Q000175:diagnosis; D000077291:Terbinafine; D013754:Tetracyclines / Q000009:adverse effects
D000319:Adrenergic beta-Antagonists; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000962:Antimalarials; D002800:Cholinesterase Inhibitors; D009281:Naphthalenes; D013754:Tetracyclines; D007372:Interferons; D008094:Lithium; D000077291:Terbinafine